The Sodium Dependent Dopamine Transporter pipeline drugs market research report outlays comprehensive information on the Sodium Dependent Dopamine Transporter targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Sodium Dependent Dopamine Transporter pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Central Nervous System, Women’s Health, Infectious Disease, and Musculoskeletal Disorders which include the indications Attention Deficit Hyperactivity Disorder (ADHD), Post-Traumatic Stress Disorder (PTSD), Female Sexual Dysfunction, Vasomotor Symptoms of Menopause (Hot Flashes), Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID), and Osteoarthritis. It also reviews key players involved in Sodium Dependent Dopamine Transporter targeted therapeutics development with respective active and dormant or discontinued products.

The Sodium Dependent Dopamine Transporter pipeline targets constitutes close to 63 molecules. Out of which, approximately 59 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 1, 6, 13, 12, 1, 1, 18, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 2 molecule.

Sodium Dependent Dopamine Transporter overview

The sodium-dependent dopamine transporter (DAT) is a membrane-bound protein that plays a crucial role in regulating dopamine levels in the brain. It is responsible for reuptaking dopamine from the synaptic cleft back into the presynaptic neuron, effectively terminating dopamine’s signaling action. This process, known as dopamine reuptake, is essential for maintaining the delicate balance of dopamine signaling in the brain.

For a complete picture of Sodium Dependent Dopamine Transporter’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.